A study presents ALPACA, a computational method for inferring clone- and allele-specific copy numbers of individual clones from multi-sample bulk DNA-sequencing data, and demonstrates its use to study metastasis trajectories.
Get the latest international news and world events from around the world.
“Engines Roared Like Exploding Suns”: Venus Aerospace Sparks Chaos as Rotating Detonation Rocket Test Ignites Groundbreaking US Leap Into the Future
IN A NUTSHELL 🚀 Venus Aerospace has tested a Rotating Detonation Rocket Engine, marking a milestone in propulsion technology. ⚡ The engine relies on supersonic explosions to generate thrust, offering higher efficiency than traditional methods. ✈️ The integration with the VDR2 ramjet could enable hypersonic vehicles to take off and land from conventional runways. 🌐
Neuroscientists Find That All Human Brains Are Connected through Extremely Low Frequency Electromagnetic Waves
For centuries, philosophers and scientists have speculated about the mysterious connections between human minds. Now, new research in neuroscience suggests that our brains may be linked in a very real, physical way — through extremely low frequency (ELF) electromagnetic waves.
Neuroscientists studying brain activity have found that the human brain not only generates its own electrical signals but also emits faint electromagnetic waves at extremely low frequencies. These ELF waves, which typically range from 1 to 30 Hertz, are so subtle that they were once thought to be biologically insignificant. However, recent experiments show that these signals can extend beyond the skull and interact with the electromagnetic environment around us.
What’s even more remarkable is that similar ELF patterns appear across different individuals, raising the possibility that brains can “tune in” to each other through this shared frequency spectrum.
FDA Approves Tonmya, First Fibromyalgia Medication in 15 Years
The US Food and Drug Administration (FDA) has approved Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine HCl, formerly known as TNX-102 SL), a novel treatment form for fibromyalgia.1 The drug is now the first in a new category of non-opioid analgesics for fibromyalgia and the first new medication for this disorder in 15 years.
The FDA’s approval cited efficacy from 2 double-blind, randomized, placebo-controlled, phase 3 clinical trials of almost 1,000 patients that evaluated Tonmya as treatment for fibromyalgia. Across both phase 3 trials, Tonmya significantly reduced daily pain scores compared with placebo at the primary endpoint of 14 weeks. In these trials, a greater percentage of patients taking Tonmya experienced a clinically meaningful (≥30%) improvement in their pain after 3 months, as compared with placebo. Across phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. The most common adverse events (incidence ≥2%) included oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.
Psychiatric Times is the connection to Psychiatry and Mental Health, featuring clinical updates, expert views, and research news in multimedia formats.
FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool
The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with nonmetastatic prostate cancer.
The authorization means the digital pathology software tool is recognized as an FDA-regulated Software as a Medical Device, Artera explained in a press release.
De Novo authorization provides a marketing pathway to classify low-or moderate-risk novel medical devices. The De Novo authorization for this specific test establishes a new product code category for future AI-powered digital pathology risk-stratification tools and enables implementation at the point of diagnosis at qualified US pathology labs, the company said.
The test analyzes digital pathology images from patients’ biopsy slides to predict long-term outcomes, such as 10-year risk for metastasis and mortality. This can help direct treatment decisions.
The FDA’s De Novo authorization for the tool establishes a new product code category for future AI-powered digital pathology risk-stratification tools.
ChatGPT in Your Clinic: Who’s the Expert Now
Patients arriving at appointments with researched information is not new, but artificial intelligence (AI) tools such as ChatGPT are changing the dynamics.
Their confident presentation can leave physicians feeling that their expertise is challenged. Kumara Raja Sundar, MD, a family medicine physician at Kaiser Permanente Burien Medical Center in Burien, Washington, highlighted this trend in a recent article published in JAMA.
A patient visited Sundar’s clinic reporting dizziness and described her symptoms with unusual precision: “It’s not vertigo, but more like a presyncope feeling.” She then suggested that the tilt table test might be useful for diagnosis.
Occasionally, patient questions reveal subtle familiarity with medical jargon. This may indicate that they either have relevant training or have studied the subject extensively.
(Artificial Intelligence is the science of making machines do things that would require intelligence if done by men — Marvin Minsky. Google helps you gain information with a search engine. AI helps you gain information through algorithms. It is the same thing. However people profit from ignorance).
Patients are showing up with ChatGPT-generated diagnoses, challenging physicians to balance empathy, evidence, and authority in the exam room.